{{Medical}}
{{noteTA
|G1=Medicine
|G2=地名
}}
{{Infobox drug
| Verifiedfields     = 
| verifiedrevid      = 
| drug_name          = 
| INN                = 
| type               = 
| image              = Johnson & Johnson COVID-19 vaccine developed by Janssen.jpg
| alt                = 
| caption            = 一瓶强生2019冠状病毒病疫苗

<!-- Vaccine data -->
| target             = 	
| vaccine_type       = 

<!-- Clinical data -->
| pronounce          = 
| tradename          = 杨森2019冠状病毒病疫苗（Janssen COVID-19 Vaccine）<ref name="Janssen COVID-19 Vaccine FDA label" /><ref>{{cite web | title=Janssen COVID-19 Emergency Use Authorization (EUA) Official Website | website=Janssen | date=2021-02-28 | url=https://www.janssencovid19vaccine.com/hcp.html | access-date=2021-02-28 | archive-date=2021-03-01 | archive-url=https://web.archive.org/web/20210301040436/https://www.janssencovid19vaccine.com/hcp.html | dead-url=no }}</ref>、COVID-19 Vaccine Janssen<ref name="Janssen CMA application" />
| Drugs.com          = 
| MedlinePlus        = 
| licence_EU         = 
| DailyMedID         = Janssen_COVID-19_Vaccine
| licence_US         = 
| pregnancy_AU       = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_category = 
| routes_of_administration = [[肌肉注射|肌肉注射]]
| class              = 
| ATCvet             = 
| ATC_prefix         = <!-- scheduled to be J07BX03 in 2022 -->
| ATC_suffix         = 
| ATC_supplemental   =

<!-- Legal status -->
| legal_status       = 欧盟<ref name="COVID-19 Vaccine Janssen EPAR">{{cite web |title=COVID-19 Vaccine Janssen EPAR |url=https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen |website=European Medicines Agency (EMA) |date=2021-03-05 |access-date=2021-03-16 |archive-date=2021-03-15 |archive-url=https://web.archive.org/web/20210315172052/https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen |dead-url=no }}</ref>、加拿大<ref name="CA authorization">{{cite web | title=Regulatory Decision Summary – Janssen COVID-19 Vaccine – Health Canada | website=[[加拿大卫生部|加拿大卫生部]] | date=2021-03-05 | url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00779 | access-date=2021-03-05 | archive-date=2021-03-05 | archive-url=https://web.archive.org/web/20210305154318/https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00779 | dead-url=no }}</ref><ref>{{cite web | title=Janssen COVID-19 Vaccine monograph | publisher=Janssen | url=https://covid-vaccine.canada.ca/info/pdf/janssen-covid-19-vaccine-pm-en.pdf | date=2021-03-05 | access-date=2021-04-14 | archive-date=2021-03-05 | archive-url=https://web.archive.org/web/20210305152243/https://covid-vaccine.canada.ca/info/pdf/janssen-covid-19-vaccine-pm-en.pdf | dead-url=no }}</ref>、美国<ref name="FDA PR 20210227">{{cite press release |title=FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine |website=U.S. Food and Drug Administration (FDA) |date=2021-02-27 |url=https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine |access-date=2021-02-27 |archive-date=2021-03-18 |archive-url=https://web.archive.org/web/20210318174827/https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine |dead-url=no }}</ref><ref name="Janssen COVID-19 Vaccine FDA label"/><ref name="FDA EUA">{{cite web |title=Janssen COVID-19 Vaccine EUA Letter of Authorization |url=https://www.fda.gov/media/146303/download |website=[[美国食品药品监督管理局|美国食品药品监督管理局]] |accessdate=2021-04-11 |archive-date=2021-03-10 |archive-url=https://web.archive.org/web/20210310103959/https://www.fda.gov/media/146303/download |dead-url=no }}</ref>

<!-- Identifiers -->
| CAS_number         = 
| CAS_supplemental   = 
| PubChem            = 
| IUPHAR_ligand      = 
| DrugBank           = DB15857
| ChemSpiderID       = 
| UNII               = JT2NS6183B
| KEGG               = 
| ChEBI_Ref          = 
| ChEBI              = 
| ChEMBL_Ref         = 
| ChEMBL             = 
| NIAID_ChemDB       = 
| PDB_ligand         = 
| synonyms           = {{ubl|
  | Ad26.COV2.S<ref name="J&J Protocol" /><ref name="J&J ENSEMBLE 2 Protocol" /><ref name="jnj">{{cite press release |url= https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate |title= Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate |access-date= 2020-09-23 |website= Johnson & Johnson |archive-date= 2020-09-23 |archive-url= https://web.archive.org/web/20200923122026/https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate |dead-url= no }}</ref>
  | JNJ-78436735<ref name="J&J Protocol" /><ref name="J&J ENSEMBLE 2 Protocol" /><ref name="jnj" />
  | Ad26COVS1<ref name="J&J Protocol" /><ref name="J&J ENSEMBLE 2 Protocol" />
  | VAC31518<ref name="J&J Protocol">{{cite web |title=A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older ENSEMBLE Protocol VAC31518COV3001; Phase 3 |url=https://www.jnj.com/coronavirus/ensemble-1-study-protocol |format=PDF |publisher=Janssen Vaccines & Prevention |access-date=2021-04-14 |archive-date=2021-02-18 |archive-url=https://web.archive.org/web/20210218014735/https://www.jnj.com/coronavirus/ensemble-1-study-protocol |dead-url=no }}</ref><ref name="J&J ENSEMBLE 2 Protocol">{{cite web | url=https://www.jnj.com/coronavirus/ensemble-2-study-protocol | format=PDF | title=A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older ENSEMBLE 2 Protocol VAC31518COV3009; Phase 3 | publisher=Janssen Vaccines & Prevention | access-date=2021-04-14 | archive-date=2021-02-25 | archive-url=https://web.archive.org/web/20210225195720/https://www.jnj.com/coronavirus/ensemble-2-study-protocol | dead-url=no }}</ref>
 }}
<!-- Chemical and physical data -->
}}
{{2019冠狀病毒病疫情邊欄}}

'''強生2019冠狀病毒病疫苗'''（{{lang-en|Johnson & Johnson COVID-19 vaccine}}，簡稱'''強生疫苗'''）是由位於[[荷兰|荷兰]][[莱顿|莱顿]]的{{link-en|杨森疫苗|Janssen Vaccines}}<ref>{{Cite web|title=Leiden developed Covid-19 vaccine submitted to EMA for approval|url=https://nltimes.nl/2021/02/16/leiden-developed-covid-19-vaccine-submitted-ema-approval|date=2021-02-16|access-date=2021-04-14|archive-date=2021-06-25|archive-url=https://web.archive.org/web/20210625093334/https://nltimes.nl/2021/02/16/leiden-developed-covid-19-vaccine-submitted-ema-approval|dead-url=no}}</ref>及其比利时母公司同時也是美国[[強生公司|強生公司]]子公司[[杨森制药|杨森制药]]（{{lang|en|Janssen Pharmaceutica}}）<ref>{{Cite web|title=Clinical trial COVID-19 vaccine candidate underway|url=https://www.janssen.com/belgium/clinical-trial-covid-19-vaccine-candidate-underway|accessdate=2021-03-13|work=Janssen Belgium|archive-date=2021-01-15|archive-url=https://web.archive.org/web/20210115154921/https://www.janssen.com/belgium/clinical-trial-covid-19-vaccine-candidate-underway|dead-url=no}}</ref>研发的[[2019冠状病毒病疫苗|2019冠状病毒病疫苗]]<ref>{{Cite web|title=EMA recommends Johnson & Johnson Covid vaccine for approval; Developed in Leiden|url=https://nltimes.nl/2021/03/11/ema-recommends-johnson-johnson-covid-vaccine-approval-developed-leiden|publisher=NL Times|access-date=2021-04-14|archive-date=2021-06-25|archive-url=https://web.archive.org/web/20210625093301/https://nltimes.nl/2021/03/11/ema-recommends-johnson-johnson-covid-vaccine-approval-developed-leiden|dead-url=no}}</ref><ref name="Globe 20200312">{{Cite news|url=https://www.bostonglobe.com/2020/03/12/business/beth-israel-is-working-with-johnson-johnson-coronavirus-vaccine/|title=Beth Israel is working with Johnson & Johnson on a coronavirus vaccine|work=The Boston Globe|date=2020-03-12|accessdate=2021-04-14|archive-date=2021-04-11|archive-url=https://web.archive.org/web/20210411150633/https://www.bostonglobe.com/2020/03/12/business/beth-israel-is-working-with-johnson-johnson-coronavirus-vaccine/|dead-url=no}}</ref>。

它是一种基于人类[[腺病毒|腺病毒]]的[[病毒载体疫苗|病毒载体疫苗]]，人类[[腺病毒|腺病毒]]经过改造後會含有能產生[[严重急性呼吸系统综合征冠状病毒2|严重急性呼吸系统综合征冠状病毒2]]病毒{{link-en|尖峰蛋白|spike protein}}的[[基因|基因]]<ref name="Janssen CMA application">{{cite press release | title=EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen | publisher=European Medicines Agency (EMA) | date=2021-02-16 | url=https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-vaccine-janssen | access-date=2021-02-16 | archive-date=2021-02-16 | archive-url=https://web.archive.org/web/20210216152545/https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-vaccine-janssen | dead-url=no }}</ref>。人体的[[免疫系统|免疫系统]]会对这种尖峰蛋白产生反应並产生[[抗体|抗体]]<ref>{{Cite web|title=COVID Vaccines: Does it Matter Which One You Get?|url=https://healthblog.uofmhealth.org/wellness-prevention/covid-vaccines-does-it-matter-which-one-you-get|accessdate=2021-03-30|date=2021-03-08|work={{link-en|Michigan Medicine}}|archive-date=2021-03-28|archive-url=https://web.archive.org/web/20210328151829/https://healthblog.uofmhealth.org/wellness-prevention/covid-vaccines-does-it-matter-which-one-you-get|dead-url=no}}</ref>。人類只需注射一剂该疫苗，且該疫苗僅需在攝氏2至8度冷藏，不用冷冻保存 <ref name="Fact sheet">{{Cite web|title=Fact Sheet for Healthcare Providers Administering Vaccine and EUA|url=https://www.fda.gov/media/146304/download|accessdate=2021-04-13|format=PDF|publisher=Janssen|archive-date=2021-04-13|archive-url=https://web.archive.org/web/20210413234636/https://www.fda.gov/media/146304/download|dead-url=no}}</ref><ref name=":3">{{Cite web|title=Johnson & Johnson's Janssen COVID-19 Vaccine Information|url=https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html|accessdate=2021-03-30|date=2021-03-23|publisher=[[美国疾病控制与预防中心|美国疾病控制与预防中心]] (CDC)|archive-date=2021-03-29|archive-url=https://web.archive.org/web/20210329230548/https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html|dead-url=no}}</ref>。

该疫苗的[[臨床試驗|臨床試驗]]于2020年6月开始，三期试验涉及约4.3万人<ref name="FDA PR 20210227" />。2021年1月29日，杨森公司宣布，在疫苗接种28天后，该疫苗预防[[2019冠狀病毒病|2019冠狀病毒病]]的有效率为66%，预防重症2019冠狀病毒病的有效率为85%<ref>{{Cite news|date=2021-01-29|title=Johnson & Johnson single-shot vaccine 85% effective against severe COVID-19 disease|work=ABC News|url=https://abcnews.go.com/Health/johnson-johnson-single-shot-vaccine-85-effective-severe/story?id=75557358|accessdate=2021-04-14|archive-date=2021-02-01|archive-url=https://web.archive.org/web/20210201092739/https://abcnews.go.com/Health/johnson-johnson-single-shot-vaccine-85-effective-severe/story?id=75557358|dead-url=no}}</ref><ref>{{Cite news|date=2021-01-29|title=Covid vaccine: Single dose Covid vaccine 66% effective|work=BBC News|url=https://www.bbc.com/news/health-55857530|accessdate=2021-01-29|archive-date=2021-01-29|archive-url=https://web.archive.org/web/20210129130751/https://www.bbc.com/news/health-55857530|dead-url=no}}</ref><ref>{{Cite web|title=J&J's Covid vaccine is 66% effective, a weapon but not a knockout punch|url=https://www.statnews.com/2021/01/29/jj-one-dose-covid-vaccine-is-66-effective-a-weapon-but-not-a-knockout-punch/|accessdate=2021-01-29|date=2021-01-29|work={{link-en|Stat (website)}}|archive-date=2021-01-29|archive-url=https://web.archive.org/web/20210129130113/https://www.statnews.com/2021/01/29/jj-one-dose-covid-vaccine-is-66-effective-a-weapon-but-not-a-knockout-punch/|dead-url=no}}</ref>，预防2019冠狀病毒病引起的住院或死亡的有效率为100%<ref name="Janssen COVID-19 Vaccine FDA label">{{Cite web|title=Janssen COVID-19 Vaccine – ad26.cov2.s injection, suspension|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14a822ff-f353-49f9-a7f2-21424b201e3b|accessdate=2021-01-27|work=DailyMed|publisher=U.S. National Institutes of Health|archive-date=2021-05-12|archive-url=https://web.archive.org/web/20210512152930/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14a822ff-f353-49f9-a7f2-21424b201e3b|dead-url=no}}</ref>。

该疫苗於2021年2月27日获得[[美国食品药品监督管理局|美国食品药品监督管理局]]的{{link-en|紧急使用授权|Emergency Use Authorization}}，2021年3月11日獲得[[欧洲药品管理局|欧洲药品管理局]]的{{link-en|有条件上市授权|Marketing authorisation}}<ref name="EU COVID-19 Vaccine Janssen"/><ref name=":1"/>。各国也在加紧疫苗接种。

==疫苗简介==
强生2019冠状病毒病疫苗采用与[[加马列亚2019冠状病毒病疫苗|卫星V疫苗]]、[[牛津－阿斯利康2019冠状病毒病疫苗|阿斯利康疫苗]]相似的技术。疫苗采用人类腺病毒为载体，与卫星V疫苗更为相似，但根据一期临床试验，其效果可能较差<ref>{{cite news |title=Russia's Sputnik V vaccine looks good in early analysis |url=https://arstechnica.com/science/2021/02/russias-sputnik-v-vaccine-looks-good-in-early-analysis/ |work=Ars Technica |date=2021-02-03 |accessdate=2021-04-20 |archive-date=2021-03-02 |archive-url=https://web.archive.org/web/20210302111800/https://arstechnica.com/science/2021/02/russias-sputnik-v-vaccine-looks-good-in-early-analysis/ |dead-url=no }}</ref>。疫苗由无复制能力的重组腺病毒26型（Ad26）载体组成，该载体包含严重急性呼吸系统综合症冠状病毒2的刺突（S）蛋白<ref name="FDA VRBPAC brief" /><ref name="J&J Protocol" />。

[[美国国家过敏和传染病研究所|美国国家过敏和传染病研究所]]疫苗研究中心和[[德州大学奥斯汀分校|德州大学奥斯汀分校]]的研究人员开发了刺突蛋白的稳定版本，其中包括两个突变，其中普通氨基酸被[[脯氨酸|脯氨酸]]取代<ref name="C&EN092920">{{cite news|title=The tiny tweak behind COVID-19 vaccines|work=Chemical & Engineering News|url=https://cen.acs.org/pharmaceuticals/vaccines/tiny-tweak-behind-COVID-19/98/i38|access-date=2021-03-01|date=2020-09-29|archive-date=2021-02-16|archive-url=https://web.archive.org/web/20210216151009/https://cen.acs.org/pharmaceuticals/vaccines/tiny-tweak-behind-COVID-19/98/i38|dead-url=no}}</ref><ref name="2020-NatGeo">{{cite news|vauthors=Kramer J|date=2020-12-31|title=They spent 12 years solving a puzzle. It yielded the first COVID-19 vaccines.|work=National Geographic|url=https://www.nationalgeographic.com/science/article/these-scientists-spent-twelve-years-solving-puzzle-yielded-coronavirus-vaccines|accessdate=2021-04-20|archive-date=2021-02-28|archive-url=https://web.archive.org/web/20210228164324/https://www.nationalgeographic.com/science/article/these-scientists-spent-twelve-years-solving-puzzle-yielded-coronavirus-vaccines|dead-url=no}}</ref><ref name="Nature073020">{{cite journal | vauthors=Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH, He X, Martinez DR, Rutten L, Bos R, van Manen D, Vellinga J, Custers J, Langedijk JP, Kwaks T, Bakkers MJ, Zuijdgeest D, Rosendahl Huber SK, Atyeo C, Fischinger S, Burke JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS, Hoffman E, Jacob-Dolan C, Kirilova M, Li Z, Lin Z, Mahrokhian SH, Maxfield LF, Nampanya F, Nityanandam R, Nkolola JP, Patel S, Ventura JD, Verrington K, Wan H, Pessaint L, Van Ry A, Blade K, Strasbaugh A, Cabus M, Brown R, Cook A, Zouantchangadou S, Teow E, Andersen H, Lewis MG, Cai Y, Chen B, Schmidt AG, Reeves RK, Baric RS, Lauffenburger DA, Alter G, Stoffels P, Mammen M, Van Hoof J, Schuitemaker H, Barouch DH | display-authors=6 |title = Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques |journal=Nature | date=2020-10|bibcode=2020Natur.586..583M |volume=586 |issue=7830 |pages=583–88 | doi=10.1038/s41586-020-2607-z | title-link=doi | pmid=32731257  }}</ref>。该疫苗的非活性成分为：[[柠檬酸一水合物|柠檬酸一水合物]]、[[柠檬酸三钠二水合物|柠檬酸三钠二水合物]]、[[乙醇|乙醇]]、2-羟丙基-β-环糊精（HBCD）（羟丙基βdex）[[聚山梨酸酯80|聚山梨酸酯80]]、[[氯化钠|氯化钠]]、[[氢氧化钠|氢氧化钠]]和[[盐酸|盐酸]]<ref name="FDA VRBPAC brief" /><ref name="Janssen COVID-19 Vaccine FDA label" />。

疫苗可在冰箱中冷藏保存数月时间<ref name="JohnsonMcGinley">{{cite news|url=https://www.washingtonpost.com/health/2021/02/04/jj-vaccine-fda/|newspaper=The Washington Post|date=2021-02-04|title=Johnson & Johnson seeks emergency FDA authorization for single-shot coronavirus vaccine|vauthors=Johnson CY, McGinley L|accessdate=2021-04-20|archive-date=2021-02-05|archive-url=https://web.archive.org/web/20210205160208/https://www.washingtonpost.com/health/2021/02/04/jj-vaccine-fda/|dead-url=no}}</ref><ref name=":0">{{Cite web|vauthors=Weintraub K|title=One-dose J&J COVID-19 vaccine meets criteria as safe and effective, FDA report finds|url=https://www.usatoday.com/story/news/health/2021/02/24/fda-finds-one-dose-j-j-covid-vaccine-meets-criteria-safe-effective/4535542001/|access-date=2021-02-05|website=USA Today|archive-date=2021-02-25|archive-url=https://web.archive.org/web/20210225000748/https://www.usatoday.com/story/news/health/2021/02/24/fda-finds-one-dose-j-j-covid-vaccine-meets-criteria-safe-effective/4535542001/|dead-url=no}}</ref><ref>{{Cite web|vauthors=Mole B|date=2021-01-29|title=COVID variants throw J&J vaccine a curveball, lowering efficacy to 66%|url=https://arstechnica.com/science/2021/01/covid-variants-throw-jj-vaccine-a-curveball-lowering-efficacy-to-66/|access-date=2021-01-26|website=Ars Technica|archive-date=2021-03-02|archive-url=https://web.archive.org/web/20210302063754/https://arstechnica.com/science/2021/01/covid-variants-throw-jj-vaccine-a-curveball-lowering-efficacy-to-66/|dead-url=no}}</ref>。与[[辉瑞－BioNTech_2019冠状病毒病疫苗|辉瑞疫苗]]、[[莫德纳2019冠状病毒病疫苗|莫德纳疫苗]]不同的是，强生疫苗采用单针接种程序，且无需冷冻运输<ref name="Chander">{{cite news |vauthors=Chander V |title=J&J files COVID-19 vaccine application with U.S. FDA |url=https://www.reuters.com/article/us-health-coronavirus-vaccines-johnson-j-idINKBN2A430V |access-date=2021-02-04 |publisher=Reuters |date=2021-02-04 |archive-date=2021-02-05 |archive-url=https://web.archive.org/web/20210205065415/https://www.reuters.com/article/us-health-coronavirus-vaccines-johnson-j-idINKBN2A430V |dead-url=no }}</ref><ref name="Fact sheet" />。每瓶疫苗含五剂<ref name=":3" />。

==不良反应==
{{seealso|2019冠状病毒病疫苗#血栓与低血小板|2019冠状病毒病疫苗#格林－巴利综合征}}
该疫苗主要的不良反应包括注射部位的疼痛、头痛、疲劳、肌肉酸痛和恶心<ref name="FDA PR 20210227" /><ref name="FDA Janssen COVID-19 Vaccine" />。这些不良反应大多数在接种疫苗后1至2天内发生，轻度至中度的不良反应则持续1至2天<ref name="FDA Janssen COVID-19 Vaccine">{{cite web | title=Janssen COVID-19 Vaccine | website=U.S. Food and Drug Administration | date=2021-03-19 | url=https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine | access-date=2021-04-07 | archive-date=2021-04-07 | archive-url=https://web.archive.org/web/20210407223157/https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine | dead-url=no }} {{PD-notice}}</ref><ref>{{cite web | title=Information about the J&J/Janssen COVID-19 Vaccine | website=Centers for Disease Control and Prevention (CDC) | date=2021-03-31 | url=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html | access-date=2021-04-07 | archive-date=2021-04-07 | archive-url=https://web.archive.org/web/20210407000636/https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html | dead-url=no }} {{PD-notice}}</ref>。

根据8例六十岁以下接种者血栓与低血小板病例，[[欧洲药品管理局|欧洲药品管理局]]4月20日称強生疫苗与罕见血栓形成之间有“可能的联系”，但总体而言接种仍然利大于弊。<ref>{{Cite web |url=https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood |title=COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets  |access-date=2021-04-20 |archive-date=2021-06-06 |archive-url=https://web.archive.org/web/20210606090115/https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood |dead-url=no }}</ref>

2021年5月，美國有研究顯示抗凝血藥「[[比伐盧定|比伐盧定]]」（Bivalirudin）可以有效治療接種強生疫苗後出現罕見血栓的人士<ref>{{Cite news|title=美研究：接種強生疫苗後出現罕見血栓　可用抗凝血藥「比伐盧定」治療|url=https://www.thestandnews.com/%E5%81%A5%E5%BA%B7/%E7%BE%8E%E7%A0%94%E7%A9%B6-%E6%8E%A5%E7%A8%AE%E5%BC%B7%E7%94%9F%E7%96%AB%E8%8B%97%E5%BE%8C%E5%87%BA%E7%8F%BE%E7%BD%95%E8%A6%8B%E8%A1%80%E6%A0%93-%E5%8F%AF%E7%94%A8%E6%8A%97%E5%87%9D%E8%A1%80%E8%97%A5-%E6%AF%94%E4%BC%90%E7%9B%A7%E5%AE%9A-%E6%B2%BB%E7%99%82/|agency=立場新聞|access-date=2021-05-07|archive-date=2021-05-07|archive-url=https://web.archive.org/web/20210507163416/https://www.thestandnews.com/%E5%81%A5%E5%BA%B7/%E7%BE%8E%E7%A0%94%E7%A9%B6-%E6%8E%A5%E7%A8%AE%E5%BC%B7%E7%94%9F%E7%96%AB%E8%8B%97%E5%BE%8C%E5%87%BA%E7%8F%BE%E7%BD%95%E8%A6%8B%E8%A1%80%E6%A0%93-%E5%8F%AF%E7%94%A8%E6%8A%97%E5%87%9D%E8%A1%80%E8%97%A5-%E6%AF%94%E4%BC%90%E7%9B%A7%E5%AE%9A-%E6%B2%BB%E7%99%82/|dead-url=no}}</ref>。

==研发历史==
[[File:Ad26.COV2.S_production_facility.jpg|缩略图]]
[[2019冠状病毒病疫情|2019冠状病毒病疫情]]期间，强生公司与[[美国卫生及公共服务部|美国卫生及公共服务部]]{{le|应急管理办公室|Office of the Assistant Secretary for Preparedness and Response}}{{le|生物医学高级研究与发展局|Biomedical Advanced Research and Development Authority}}合作，以非盈利性原则研发疫苗<ref name="Vecchione_2020">{{cite web|url=https://njbiz.com/jj-collaborates-accelerate-covid-19-vaccine-development/|title=J&J collaborates to accelerate COVID-19 vaccine development|vauthors=Vecchione A|date=2020-03-13|website=NJBIZ|access-date=2020-04-22|archive-date=2021-01-22|archive-url=https://web.archive.org/web/20210122050240/https://njbiz.com/jj-collaborates-accelerate-covid-19-vaccine-development/|dead-url=no}}</ref><ref>{{cite web|url=https://www.wspa.com/news/prisma-health-collaborates-with-ethicon-inc-to-make-distribute-vesper-ventilator-expansion-splitter-device/|title=Prisma Health collaborates with Ethicon Inc. to make, distribute VESper Ventilator Expansion Splitter Device|date=2020-04-06|website=WSPA 7News|access-date=2020-04-22|archive-date=2021-01-22|archive-url=https://web.archive.org/web/20210122191226/https://www.wspa.com/news/prisma-health-collaborates-with-ethicon-inc-to-make-distribute-vesper-ventilator-expansion-splitter-device/|dead-url=no}}</ref>。强生公司表示，其疫苗项目将“处于非营利水平”，因为该公司将其视为“以最快最好的方式找到世界上所有合作，来实现这一目标”<ref>{{cite web|url=https://news.sky.com/story/coronavirus-johnson-johnson-vows-to-make-not-for-profit-vaccine-11966292|title=Coronavirus: Johnson & Johnson vows to make 'not-for-profit' vaccine|website=Sky News|access-date=2020-04-22|archive-date=2021-01-21|archive-url=https://web.archive.org/web/20210121042014/https://news.sky.com/story/coronavirus-johnson-johnson-vows-to-make-not-for-profit-vaccine-11966292|dead-url=no}}</ref>。

杨森疫苗公司则与[[贝斯以色列女执事医疗中心|贝斯以色列女执事医疗中心]]合作，根据用于生产{{le|埃博拉疫苗|Ebola vaccine}}的相同技术，负责开发候选疫苗<ref name="Globe 20200312" /><ref>{{cite news | title=A Beth Israel researcher helped create a COVID-19 vaccine that awaits approval. It could be a 'game changer' | website=The Boston Globe | date=2021-01-16 | url=https://www.bostonglobe.com/2021/01/16/nation/beth-israel-researcher-awaits-approval-covid-19-vaccine-he-helped-create/ | access-date=2021-02-28 | archive-date=2021-03-01 | archive-url=https://web.archive.org/web/20210301003948/https://www.bostonglobe.com/2021/01/16/nation/beth-israel-researcher-awaits-approval-covid-19-vaccine-he-helped-create/ | dead-url=no }}</ref><ref>{{cite web | title=FDA grants third COVID-19 vaccine, developed in part at BIDMC, emergency use authorization | website=Beth Israel Deaconess Medical Center (BIDMC) | date=2021-02-27 | url=https://www.bidmc.org/about-bidmc/news/2021/01/data-shows-bidmc-vaccine-collab-met-co-primary-endpoints | first=Jacqueline | last=Mitchell | first2=Chloe | last2=Meck | access-date=2021-02-28 | archive-date=2021-02-27 | archive-url=https://web.archive.org/web/20210227234558/https://www.bidmc.org/about-bidmc/news/2021/01/data-shows-bidmc-vaccine-collab-met-co-primary-endpoints | dead-url=no }}</ref>。

临床前试验表明，该疫苗可有效保护[[仓鼠|仓鼠]]和[[恒河猕猴|恒河猕猴]]免受SARS-CoV-2侵害<ref name=":4">{{cite journal | vauthors = Calvo Fernández E, Zhu LY | title = Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future | journal = British Journal of Clinical Pharmacology | volume = n/a | issue = n/a | date = 2020-12| pmid = 33289156 | pmc = 7753785 | doi = 10.1111/bcp.14686 }}</ref>。

===一、二期临床试验===
2020年6月，强生公司和[[美国国家过敏和传染病研究所|美国国家过敏和传染病研究所]]确认，计划于2020年9月开始该疫苗的临床试验，并可能进行一、二a期人类临床试验。试验工作从7月下半月开始加速发展<ref>{{cite web|vauthors=Coleman J|date=10 June 2020|title=Final testing stage for potential coronavirus vaccine set to begin in July|url=https://thehill.com/policy/healthcare/501999-final-testing-stage-for-coronavirus-vaccine-could-begin-in-july-report|access-date=2020-06-11|website=TheHill|archive-date=2021-01-10|archive-url=https://web.archive.org/web/20210110124831/https://thehill.com/policy/healthcare/501999-final-testing-stage-for-coronavirus-vaccine-could-begin-in-july-report|dead-url=no}}</ref><ref>{{cite web|title=Moderna, AstraZeneca and J&J coronavirus shots rev up for NIH tests beginning in July: WSJ|url=https://www.fiercepharma.com/vaccines/nih-preps-late-stage-studies-moderna-az-and-j-j-coronavirus-vaccines-wsj|access-date=2020-06-11|website=FiercePharma|archive-date=2021-01-21|archive-url=https://web.archive.org/web/20210121042714/https://www.fiercepharma.com/vaccines/nih-preps-late-stage-studies-moderna-az-and-j-j-coronavirus-vaccines-wsj|dead-url=no}}</ref><ref>{{cite web|title=Johnson & Johnson to start human testing of COVID-19 vaccine next week|url=https://www.fiercepharma.com/vaccines/j-j-to-start-human-testing-covid-19-vaccine-next-week-exec|access-date=2020-07-20|website=FiercePharma|archive-date=2021-01-22|archive-url=https://web.archive.org/web/20210122044104/https://www.fiercepharma.com/vaccines/j-j-to-start-human-testing-covid-19-vaccine-next-week-exec|dead-url=no}}</ref>。

一、二a期试验自2020年7月15日招募首位受试者开始，并在比利时和美国招募了研究参与者<ref name="phase1-2a_clinicaltrialsgov">{{cite web|title=A Study of Ad26.COV2.S in Adults (COVID-19)|url=https://clinicaltrials.gov/ct2/show/NCT04436276|access-date=2021-02-19|website=ClinicalTrials.gov|archive-date=2020-09-16|archive-url=https://web.archive.org/web/20200916063346/https://clinicaltrials.gov/ct2/show/NCT04436276|dead-url=no}}</ref>。一、二a期试验的中期结果确定了疫苗的安全性、反应原性和免疫原性。根据报告，注射一剂疫苗后的29天内，可确保90%的参与者具有中和病毒所需的足够抗体。在57天后，所有参与者全部具有抗体<ref name="NEJM">{{cite journal |vauthors=Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H |display-authors=6 |date=13 January 2021 |title=Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine |journal=New England Journal of Medicine |volume= |issue= |pages= |pmid=33440088 |pmc=7821985}}</ref><ref name="phase1-2a">{{cite press release |title=Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine |url=https://www.jnj.com/johnson-johnson-covid-19-vaccine-candidate-interim-phase-1-2a-data-published-in-new-england-journal-of-medicine |access-date=2021-01-16 |website=Johnson & Johnson |archive-date=2021-01-17 |archive-url=https://web.archive.org/web/20210117005941/https://www.jnj.com/johnson-johnson-covid-19-vaccine-candidate-interim-phase-1-2a-data-published-in-new-england-journal-of-medicine |dead-url=no }}</ref>。

===三期临床试验===
三期临床试验命名为“ENSEMBLE”，于2020年9月开始招募，并于2020年12月17日完成招募。此次临床试验是随机、双盲、[[安慰剂对照|安慰剂对照]]的试验，旨在与18岁及以上成年人的安慰剂相比，评估单剂量疫苗的安全性和有效性。研究参与者在第一天接受疫苗的单次肌肉注射，剂量为5×10{{sup|10}}病毒颗粒<ref>{{cite web|title=Fourth large-scale COVID-19 vaccine trial begins in the United States|url=https://www.nih.gov/news-events/news-releases/fourth-large-scale-covid-19-vaccine-trial-begins-united-states|access-date=2021-01-30|website=National Institutes of Health|archive-date=2021-01-30|archive-url=https://web.archive.org/web/20210130164337/https://www.nih.gov/news-events/news-releases/fourth-large-scale-covid-19-vaccine-trial-begins-united-states|dead-url=no}}</ref>。但因一名志愿者出现不良反应，试验于10月12日暂停。试验在11天后恢复<ref>{{cite news |author1=Katherine J. Wu |author2=Carl Zimmer |author3=Sharon LaFraniere |author4=Noah Weiland |title=Two Companies Restart Virus Trials in U.S. After Safety Pauses |url=https://www.nytimes.com/2020/10/23/health/covid-vaccine-astrazeneca-johnson-and-johnson.html |accessdate=2021-02-26 |work=[[纽约时报|纽约时报]] |date=2020-10-23 |archive-date=2020-10-25 |archive-url=https://web.archive.org/web/20201025112028/https://www.nytimes.com/2020/10/23/health/covid-vaccine-astrazeneca-johnson-and-johnson.html |dead-url=no }}</ref>。2021年1月29日，杨森从此次临床试验数据的中期分析中公布安全性和有效性数据。该数据表明，该疫苗在所有志愿者中预防接种后28天内，重度COVID-19疾病预防有效率为66%。中期分析则是基于阿根廷、巴西、智利、哥伦比亚、墨西哥、秘鲁、南非和美国的43783名成年志愿者中的468例COVID-19征候病例。在疫苗试验组中，没有与COVID-19相关的死亡个案，而在安慰剂组中，有5例与COVID-19相关的死亡个案。在试验期间，所有参与者未观察到过敏反应<ref name="jnj_29Jan2021">{{cite press release|title=Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial|url=https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial|access-date=2021-02-01|website=Johnson & Johnson|archive-date=2021-01-31|archive-url=https://web.archive.org/web/20210131233737/https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial|dead-url=no}}</ref>。

第二次三期临床试验于2020年11月12日开始招募。第二次三期临床试验与第一次的不同之处在于，其研究参与者将分别接受两次肌内注射，分别在第1天和第57天<ref name="ensemble2">{{cite web|title=A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)|url=https://clinicaltrials.gov/ct2/show/NCT04614948|access-date=2021-01-30|website=ClinicalTrials.gov|archive-date=2021-01-29|archive-url=https://web.archive.org/web/20210129220848/https://clinicaltrials.gov/ct2/show/NCT04614948|dead-url=no}}</ref>。

強生疫苗在第三期臨床測試的數據、安全性及有效性的論文，於2021年4月21日刊登在《[[新英格蘭醫學期刊|新英格蘭醫學期刊]]》發表<ref name="nejm-2021-04-21">{{cite journal |author1=Jerald Sadoff, M.D., Glenda Gray, M.B., B.Ch., An Vandebosch, Ph.D., Vicky Cárdenas, Ph.D., Georgi Shukarev, M.D., Beatriz Grinsztejn, M.D., Paul A. Goepfert, M.D., Carla Truyers, Ph.D., Hein Fennema, Ph.D., Bart Spiessens, Ph.D., Kim Offergeld, M.Sc., Gert Scheper, Ph.D., Kimberly L. Taylor, Ph.D., Merlin L. Robb, M.D., John Treanor, M.D., Dan H. Barouch, M.D., Jeffrey Stoddard, M.D., Martin F. Ryser, M.D., Mary A. Marovich, M.D., Kathleen M. Neuzil, M.D., Lawrence Corey, M.D., Nancy Cauwenberghs, Ph.D., Tamzin Tanner, Ph.D., Karin Hardt, Ph.D., Javier Ruiz-Guiñazú, M.D., Mathieu Le Gars, Ph.D., Hanneke Schuitemaker, Ph.D., Johan Van Hoof, M.D., Frank Struyf, M.D., Macaya Douoguih, M.D. |title=Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 |journal=The New England Journal of Medicine |date=2021-04-21 |url=https://www.nejm.org/doi/full/10.1056/NEJMoa2101544 |accessdate=2021-04-23 |archive-url=https://web.archive.org/web/20210422001326/https://www.nejm.org/doi/full/10.1056/NEJMoa2101544 |archive-date=2021-04-22 |dead-url=no }}</ref>。

==生产==
2020年4月，强生公司与Catalent建立合作关系，以在Catalent位于[[印第安纳州|印第安纳州]][[布卢明顿_(印第安纳州)|布卢明顿]]的工厂大规模生产疫苗<ref>{{cite web|vauthors=Vecchione A|date=29 April 2020|title=Catalent to lead US manufacturing for J&J's lead COVID-19 vaccine candidate|url=https://njbiz.com/catalent-lead-us-manufacturing-jjs-lead-covid-19-vaccine-candidate/|access-date=2020-11-13|website=NJBIZ|archive-date=2020-11-19|archive-url=https://web.archive.org/web/20201119131151/https://njbiz.com/catalent-lead-us-manufacturing-jjs-lead-covid-19-vaccine-candidate/|dead-url=no}}</ref>。2020年7月，合作关系扩大到包括Catalent在[[意大利|意大利]][[阿纳尼|阿纳尼]]的工厂<ref>{{cite web|title=J&J expands COVID-19 vaccine pact with Catalent for finishing work at Italian facility|url=https://www.fiercepharma.com/manufacturing/j-j-expands-covid-19-vaccine-pact-catalent-for-finishing-work-at-italian-facility|access-date=2020-11-13|website=FiercePharma|archive-date=2020-10-25|archive-url=https://web.archive.org/web/20201025143810/https://www.fiercepharma.com/manufacturing/j-j-expands-covid-19-vaccine-pact-catalent-for-finishing-work-at-italian-facility|dead-url=no}}</ref>。

2020年7月，强生承诺向美国提供多达3亿剂疫苗，其中1亿剂为前期供应，另外还包括2,000万剂作为后期选择。此次交易总价值超过10亿美元，由生物医学高级研究与开发局和[[美国国防部|美国国防部]]资助<ref>{{cite press release|date=5 August 2020|title=HHS, DOD Collaborate With Johnson & Johnson to Produce Millions of COVID-19 Investigational Vaccine Doses|url=https://www.hhs.gov/about/news/2020/08/05/hhs-dod-collaborate-with-johnson-and-johnson-to-produce-millions-of-covid-19-investigational-vaccine-doses.html|access-date=2020-08-06|website=HHS.gov|archive-date=2020-12-12|archive-url=https://web.archive.org/web/20201212113629/https://www.hhs.gov/about/news/2020/08/05/hhs-dod-collaborate-with-johnson-and-johnson-to-produce-millions-of-covid-19-investigational-vaccine-doses.html|dead-url=no}}</ref><ref name="Aug2020USGov">{{cite press release|title=Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine|url=https://www.jnj.com/johnson-johnson-announces-agreement-with-u-s-government-for-100-million-doses-of-investigational-covid-19-vaccine|access-date=2020-08-06|website=Johnson & Johnson|archive-date=2021-02-18|archive-url=https://web.archive.org/web/20210218142154/https://www.jnj.com/johnson-johnson-announces-agreement-with-u-s-government-for-100-million-doses-of-investigational-covid-19-vaccine|dead-url=no}}</ref>。同年8月5日，双方确认交易<ref>{{cite web|url=https://www.voanews.com/covid-19-pandemic/us-pay-johnson-and-johnson-1-billion-covid-19-vaccine|title=US to Pay Johnson and Johnson $1 Billion for COVID-19 Vaccine|access-date=2020-08-05|website=Voice of America|archive-date=2021-01-24|archive-url=https://web.archive.org/web/20210124115349/https://www.voanews.com/covid-19-pandemic/us-pay-johnson-and-johnson-1-billion-covid-19-vaccine|dead-url=no}}</ref>。

2020年9月，Grand River无菌制造公司与强生公司达成协议，将在[[密歇根州|密歇根州]][[大急流城_(密歇根州)|大急流城]]的工厂支持疫苗的制造，包括技术转让以及灌装和精加工制造<ref name="contract">{{Cite web|url=https://www.contractpharma.com/contents/view_online-exclusives/2020-11-03/ramping-up-covid-19-vaccine-fill-and-finish-capacity/|title=Ramping Up COVID-19 Vaccine Fill and Finish Capacity|website=Contract Pharma|date=2020-11-03|access-date=2021-04-20|archive-date=2021-01-28|archive-url=https://web.archive.org/web/20210128053930/https://www.contractpharma.com/contents/view_online-exclusives/2020-11-03/ramping-up-covid-19-vaccine-fill-and-finish-capacity/|dead-url=no}}</ref>。

2020年12月，强生公司与西班牙Reig Jofre制药公司达成协议，将在Reig Jofre的巴塞罗那工厂生产疫苗<ref>{{Cite news|url=https://www.reuters.com/article/us-reig-jofre-johnson-johnson-vaccine-idUSKBN28P0V2|title=Spain's Reig Jofre to manufacture J&J's COVID-19 vaccine, shares soar|vauthors=Faus J, Allen N|date=2020-12-15|publisher=Reuters|accessdate=2021-04-20|archive-date=2021-02-09|archive-url=https://web.archive.org/web/20210209173836/https://www.reuters.com/article/us-reig-jofre-johnson-johnson-vaccine-idUSKBN28P0V2|dead-url=no}}</ref>。一旦欧洲药品管理局在2021年3月之前批准该疫苗，强生公司可能会从2021年4月开始，向[[欧洲联盟成员国|欧盟各成员国]]提供疫苗<ref name="Francesco">{{Cite news|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-eu-johnson-idUSKBN29I1EM|title=J&J COVID-19 vaccine could be available in Europe in April: source|vauthors=Guarascio F|date=2021-01-13|publisher=Reuters|accessdate=2021-04-20|archive-date=2021-01-30|archive-url=https://web.archive.org/web/20210130000814/https://www.reuters.com/article/us-health-coronavirus-vaccine-eu-johnson-idUSKBN29I1EM|dead-url=no}}</ref><ref>{{cite news |title=EMA expected to approve Johnson & Johnson vaccine by March – CEO of Janssen Italy to paper |url=https://www.reuters.com/article/us-health-coronavirus-italy-vaccine-idUSKBN2AA0JG |access-date=2021-02-13 |publisher=Reuters |date=2021-02-10 |archive-date=2021-02-12 |archive-url=https://web.archive.org/web/20210212190639/https://www.reuters.com/article/us-health-coronavirus-italy-vaccine-idUSKBN2AA0JG |dead-url=no }}</ref>。从2021年第二季度开始，该工厂将每年生产5000万剂疫苗<ref>{{cite news |last1=Staff |first1=Reuters |title=Spain's Reig Jofre to have capacity for 50 million COVID-19 vaccine doses a year |url=https://www.reuters.com/article/us-health-coronavirus-reig-jofre-vaccine-idUSKBN27T0UY |accessdate=2021-04-15 |work=Reuters |date=2020-11-13 |language=en |archive-date=2021-04-15 |archive-url=https://web.archive.org/web/20210415154342/https://www.reuters.com/article/us-health-coronavirus-reig-jofre-vaccine-idUSKBN27T0UY |dead-url=no }}</ref>。

2020年8月，强生与美国联邦政府签署了一项价值10亿美元的合同，同意在疫苗获得美国食品和药物管理局的批准或紧急使用授权后，向美国提供1亿剂疫苗<ref name="Aug2020USGov"/>。根据与美国政府达成的协议，强生的目标是到2021年2月底生产1200万剂，到2021年4月底生产超过6000万剂，到2021年6月底生产超过1亿剂。然而，强生公司在2021年1月承认，由于生产方面的延迟，可能会阻止其履行2月底之前交付给美国的1200万剂的合同<ref>{{cite news| url=https://www.nytimes.com/2021/01/13/health/covid-vaccine-johnson-johnson.html| title=Johnson & Johnson Expects Vaccine Results Soon but Lags in Production| work=The New York Times| date=2021-01-13| vauthors=Zimmer C, LaFraniere S, Weiland N| accessdate=2021-04-20| archive-date=2021-01-15| archive-url=https://web.archive.org/web/20210115133230/https://www.nytimes.com/2021/01/13/health/covid-vaccine-johnson-johnson.html| dead-url=no}}</ref>。2021年2月，强生公司高管在美国国会作证。但强生公司表示，该公司可以在3月底之前向美国政府交付2千万剂，在2021年上半年交付1亿剂<ref>{{cite web | vauthors=Owermohle S | title=Johnson & Johnson says it can provide 20M vaccine doses by late March | website=Politico | date=2021-02-22 | url=https://www.politico.com/news/2021/02/22/johnson-johnson-vaccine-march-470994 | access-date=2021-04-01 | archive-date=2021-03-23 | archive-url=https://web.archive.org/web/20210323163912/https://www.politico.com/news/2021/02/22/johnson-johnson-vaccine-march-470994 | dead-url=no }}</ref>。

2021年2月，[[赛诺菲|赛诺菲]]与强生公司达成一项协议，要求赛诺菲在法国Marcy-l'Étoile工厂提供支持和基础设施。一旦赛诺菲获得授权，赛诺菲每月可生产约1200万剂强生疫苗<ref>{{cite news | title=France's Sanofi to help Johnson & Johnson manufacture COVID-19 vaccine | website=Reuters | date=2021-02-22 | url=https://www.reuters.com/article/us-health-coronavirus-johnson-johnson-sa-idUSKBN2AM126 | access-date=2021-04-01 | archive-date=2021-04-15 | archive-url=https://web.archive.org/web/20210415154342/https://www.reuters.com/article/us-health-coronavirus-johnson-johnson-sa-idUSKBN2AM126 | dead-url=no }}</ref>。

2021年3月，[[默克公司|默克公司]]和强生公司达成一项交易，要求默克公司在美国的两个工厂生产强生疫苗，以根据《[[国防生产法|国防生产法]]》的规定帮助扩大疫苗的生产能力<ref>{{cite press release | title=Biden Administration Announces Historic Manufacturing Collaboration Between Merck and Johnson & Johnson to Expand Production of COVID-19 Vaccines | website=HHS | date=2021-03-02 | url=https://www.hhs.gov/about/news/2021/03/02/biden-administration-announces-historic-manufacturing-collaboration-between-merck-johnson-johnson-expand-production-covid-19-vaccines.html | access-date=2021-03-04 | archive-date=2021-03-03 | archive-url=https://web.archive.org/web/20210303203739/https://www.hhs.gov/about/news/2021/03/02/biden-administration-announces-historic-manufacturing-collaboration-between-merck-johnson-johnson-expand-production-covid-19-vaccines.html | dead-url=no }}</ref>。同月，在[[巴尔的摩|巴尔的摩]]{{le|新兴生物科技公司|Emergent BioSolutions}}运营的一家工厂发生人为失误，由于员工弄混药剂成分，导致多达1500万剂强生疫苗变质及报废<ref>{{Cite news|vauthors=LaFraniere S, Weiland N|date=2021-03-31|title=Factory Mix-Up Ruins Up to 15 Million Vaccine Doses From Johnson & Johnson|work=The New York Times|url=https://www.nytimes.com/2021/03/31/us/politics/johnson-johnson-coronavirus-vaccine.html|access-date=2021-04-01|archive-date=2021-04-01|archive-url=https://web.archive.org/web/20210401001259/https://www.nytimes.com/2021/03/31/us/politics/johnson-johnson-coronavirus-vaccine.html|dead-url=no}}</ref>。强生公司3月31日向媒体证实，这家工厂生产的某批次强生疫苗“质量不达标”，涉事疫苗处于试生产阶段，该厂所产强生疫苗尚未获美国食品和药物管理局批准投用于美国市场<ref>{{cite news |title=一个疏忽，1500万剂疫苗报废 |url=https://finance.sina.com.cn/jjxw/2021-04-01/doc-ikmxzfmk0633276.shtml |accessdate=2021-04-15 |work=参考消息 |date=2021-04-01 |archive-date=2021-04-16 |archive-url=https://web.archive.org/web/20210416204402/https://finance.sina.com.cn/jjxw/2021-04-01/doc-ikmxzfmk0633276.shtml |dead-url=no }}</ref>。

2021年6月，美国食品药品监督管理局表示，Emergent BioSolutions Inc在巴尔的摩工厂生产的强生疫苗发生操作错误，混淆了强生和阿斯利康的生产成分后，4月被FDA下令暂停生产，这导致多个批次的强生疫苗无法使用。该机构和厂家都未透露损失疫苗的具体数字。《纽约时报》援引知情人士透露，可能有6000万剂疫苗受到波及。欧盟表示，强生公司很可能不会在预定的6月底之前向欧盟运送5500万剂疫苗<ref>{{cite news |title=操作错误！ 大批强生疫苗无法使用 |url=https://www.dw.com/zh/%E6%93%8D%E4%BD%9C%E9%94%99%E8%AF%AF-%E5%A4%A7%E6%89%B9%E5%BC%BA%E7%94%9F%E7%96%AB%E8%8B%97%E6%97%A0%E6%B3%95%E4%BD%BF%E7%94%A8/a-57866371 |accessdate=2021-06-14 |work=德国之声中文网 |date=2021-06-12 |archive-date=2021-06-20 |archive-url=https://web.archive.org/web/20210620001742/https://www.dw.com/zh/%E6%93%8D%E4%BD%9C%E9%94%99%E8%AF%AF-%E5%A4%A7%E6%89%B9%E5%BC%BA%E7%94%9F%E7%96%AB%E8%8B%97%E6%97%A0%E6%B3%95%E4%BD%BF%E7%94%A8/a-57866371 |dead-url=no }}</ref>。南非监管机构宣布，南非将不会分发使用该批次的疫苗，正与强生公司商量换货<ref>{{cite news |author1=王宏彬 |title=数百万剂强生疫苗报废　南非要求换货 |url=http://www.xinhuanet.com/world/2021-06/14/c_1211199635.htm |accessdate=2021-06-14 |work=新华网 |date=2021-06-14 |archive-date=2021-06-14 |archive-url=https://web.archive.org/web/20210614030146/http://www.xinhuanet.com/world/2021-06/14/c_1211199635.htm |dead-url=no }}</ref>。

==获批与供应==
{{seealso|2019冠状病毒病疫苗授权列表}}
===欧盟===
2020年12月1日开始，该候选疫苗的临床试验已经由[[欧洲药品管理局|欧洲药品管理局]]人用药品委员会进行“滚动审查”，以加快对预期的有条件销售许可申请<ref name="Francesco"/><ref name=":2">{{cite press release|url=https://www.jnj.com/our-company/johnson-johnson-announces-initiation-of-rolling-submission-for-its-single-dose-janssen-covid-19-vaccine-candidate-with-the-european-medicines-agency|title=Johnson & Johnson Announces Initiation of Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with the European Medicines Agency|publisher=Johnson & Johnson|date=2020-12-01|access-date=2021-04-20|archive-date=2021-01-27|archive-url=https://web.archive.org/web/20210127221955/https://www.jnj.com/our-company/johnson-johnson-announces-initiation-of-rolling-submission-for-its-single-dose-janssen-covid-19-vaccine-candidate-with-the-european-medicines-agency|dead-url=no}}</ref>。2021年2月16日，杨森向欧洲药品管理局申请该疫苗的有条件销售许可<ref name="Janssen CMA application"/>。2021年3月11日，欧盟委员会批准疫苗上市<ref name="COVID-19 Vaccine Janssen EPAR" /><ref name="EU COVID-19 Vaccine Janssen">{{cite web | title=COVID-19 Vaccine Janssen | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1525.htm | access-date=2021-03-16 | archive-date=2021-03-11 | archive-url=https://web.archive.org/web/20210311162213/https://ec.europa.eu/health/documents/community-register/html/h1525.htm | dead-url=no }}</ref>。该疫苗计划于4月下半月开始发货，杨森亦承诺到2021年将向欧盟运送至少2亿剂疫苗<ref>{{cite news | vauthors=Muvija M, Aripaka P | title=Europe clears J&J's single-shot COVID-19 vaccine as roll-out falters | website=Reuters | date=2021-03-11 | url=https://www.reuters.com/article/us-health-coronavirus-eu-johnson-johnson-idUSKBN2B31SW | access-date=2021-03-16 | archive-date=2021-03-15 | archive-url=https://web.archive.org/web/20210315223644/https://www.reuters.com/article/us-health-coronavirus-eu-johnson-johnson-idUSKBN2B31SW | dead-url=no }}</ref>。

2021年4月9日，欧洲药品管理局表示，在发现4起接种强生疫苗后出现与低血小板有关的严重罕见血栓案例，其中一人死亡。欧洲药品管理局表示当局正在审查接种强生疫苗后出现的血栓案例<ref>{{cite news |last1=廖慧婷 |first1=文 / |title=欧洲药管局：正审查强生疫苗与血栓个案是否有关 |url=https://www.zaobao.com.sg/realtime/world/story20210409-1138225 |accessdate=2021-04-18 |work=联合早报 |date=2021-04-09 |archive-date=2021-04-22 |archive-url=https://web.archive.org/web/20210422092229/https://www.zaobao.com.sg/realtime/world/story20210409-1138225 |dead-url=no }}</ref>。4月13日，强生宣布將延後在歐洲推出疫苗<ref>{{cite news |title=嬌生疫苗6人接種後出現血栓 暫緩於歐洲推出 |url=https://www.cna.com.tw/news/firstnews/202104140031.aspx |accessdate=2021-04-18 |work=中央通讯社 |date=2021-04-14 |language=zh-TW |archive-date=2021-05-31 |archive-url=https://web.archive.org/web/20210531111005/https://www.cna.com.tw/news/firstnews/202104140031.aspx |dead-url=no }}</ref>。

2021年4月14日，瑞典卫生局宣布，将暂缓开始使用强生疫苗接种的打算。法国表示将继续为55岁以上的人接种强生疫苗<ref>{{cite news |last1=廖慧婷 |first1=文 / |title=瑞典暂停强生疫苗接种计划 欧洲监管机构加速审查该疫苗 |url=https://www.zaobao.com.sg/realtime/world/story20210414-1139423 |accessdate=2021-04-18 |work=联合早报 |date=2021-04-14 |archive-date=2021-04-19 |archive-url=https://web.archive.org/web/20210419215808/https://www.zaobao.com.sg/realtime/world/story20210414-1139423 |dead-url=no }}</ref>。

4月20日，强生公司宣布重启其在欧洲的接种活动，而欧洲药品管理局建议在其标签上加注安全警示标语<ref>{{cite news |last1=陈慧璋 |first1=文 / |title=欧洲重启接种强生疫苗并建议加注警示标签 |url=https://www.zaobao.com.sg/realtime/world/story20210421-1141001 |accessdate=2021-04-21 |work=联合早报 |date=2021-04-21 |archive-date=2021-04-25 |archive-url=https://web.archive.org/web/20210425222348/https://www.zaobao.com.sg/realtime/world/story20210421-1141001 |dead-url=no }}</ref>。欧洲药品管理局表示，该疫苗可能与罕见类型的血栓病例有关联，但是该疫苗的益处要大于风险<ref>{{cite news |title=欧洲药管局发现强生疫苗可能与血栓有联系 |url=https://www.voachinese.com/a/ema-finds-link-between-johnson-and-johnson-vaccine-and-blood-clots-20210420/5860534.html |accessdate=2021-04-21 |work=美国之音 |date=2021-04-21 |language=zh |archive-date=2021-04-28 |archive-url=https://web.archive.org/web/20210428065944/https://www.voachinese.com/a/ema-finds-link-between-johnson-and-johnson-vaccine-and-blood-clots-20210420/5860534.html |dead-url=no }}</ref>。

5月3日，丹麥國家衛生局宣佈停止接種強生2019冠狀病毒病疫苗，丹麥衛生局認為接種強生疫苗的益處未必大於风险<ref>{{cite news |title=丹麦宣布停用强生新冠疫苗 |url=http://www.xinhuanet.com/world/2021-05/04/c_1127406678.htm |accessdate=2021-05-04 |archive-date=2021-05-04 |archive-url=https://web.archive.org/web/20210504124732/http://www.xinhuanet.com/world/2021-05/04/c_1127406678.htm |dead-url=no }}</ref>。

===美国===
2021年2月4日，杨森生物技术公司向[[美国食品药品监督管理局|美国食品药品监督管理局]]申请紧急使用授权。美国食药监局宣布，疫苗和相关生物产品咨询委员会将于2月26日开会审议该申请<ref name="JohnsonMcGinley"/><ref name="Chander"/><ref>{{cite press release |title=FDA Announces Advisory Committee Meeting to Discuss Janssen Biotech Inc.'s COVID-19 Vaccine Candidate |url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-janssen-biotech-incs |publisher=U.S. Food and Drug Administration (FDA) |access-date=2021-02-04 |date=2021-02-04 |archive-date=2021-02-05 |archive-url=https://web.archive.org/web/20210205003850/https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-janssen-biotech-incs |dead-url=no }}</ref><ref>{{cite web | title=Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Announcement | publisher=U.S. Food and Drug Administration (FDA) | url=https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-february-26-2021-meeting-announcement | access-date=2021-02-19 | archive-date=2021-02-16 | archive-url=https://web.archive.org/web/20210216224508/https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-february-26-2021-meeting-announcement | dead-url=no }}</ref>。强生公司宣布，计划在获得紧急使用授权后立即发货<ref name="jnj_29Jan2021" />。2月24日，在疫苗和相关生物产品咨询委员会召开会议之前，发布了杨森和美国食药监局的简报文件。美国食药监局文件建议授予疫苗的紧急使用授权，其结论是疫苗的临床试验结果和安全性数据与美国食药监局针对COVID-19疫苗的紧急使用授权指南一致<ref>{{cite report |title=Janssen Biotech, Inc. COVID-19 Vaccine Ad26.COV2.S VRBPAC Briefing Document |publisher=Janssen Biotech |url=https://www.fda.gov/media/146219/download |format=PDF |date= |access-date=2021-04-20 |archive-date=2021-02-25 |archive-url=https://web.archive.org/web/20210225010605/https://www.fda.gov/media/146219/download |dead-url=no }}</ref><ref>{{cite report |title=Janssen Biotech, Inc. COVID-19 Vaccine Ad26.COV2.S VRBPAC Briefing Document Addendum |publisher=Janssen Biotech |url=https://www.fda.gov/media/146218/download |format=PDF |date= |access-date=2021-04-20 |archive-date=2021-02-24 |archive-url=https://web.archive.org/web/20210224233750/https://www.fda.gov/media/146218/download |dead-url=no }}</ref><ref name="FDA VRBPAC brief">{{cite report |title=FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 |publisher=U.S. Food and Drug Administration (FDA) |url=https://www.fda.gov/media/146217/download |format=PDF |lay-url=https://www.statnews.com/2021/02/24/new-data-shed-light-on-efficacy-of-jjs-single-dose-vaccine-against-covid-19/ |date= |access-date=2021-04-20 |archive-date=2021-04-29 |archive-url=https://web.archive.org/web/20210429162601/https://www.fda.gov/media/146217/download |dead-url=no }} {{PD-notice}}</ref><ref>{{cite web|vauthors=Christensen J|url=https://www.cnn.com/2021/02/24/health/johnson-vaccine-fda-analysis/index.html|title=FDA says Johnson & Johnson Covid-19 vaccine meets requirements for emergency use authorization|publisher=CNN|date=2021-02-24|access-date=2021-04-20|archive-date=2021-05-13|archive-url=https://web.archive.org/web/20210513111638/https://www.cnn.com/2021/02/24/health/johnson-vaccine-fda-analysis/index.html|dead-url=no}}</ref>。2月26日，疫苗和相关生物产品咨询委员会成员就此进行投票，最终以22票（全票赞成）的结果，建议为该疫苗授予紧急使用授权<ref>{{cite web|vauthors=Lovelace Jr B|date=2021-02-26|title=FDA panel unanimously recommends third Covid vaccine as J&J wins key vote in path to emergency use|url=https://www.cnbc.com/2021/02/26/johnson-and-johnson-covid-vaccine-fda-panel-recommends-emergency-use.html|access-date=2021-04-20|archive-date=2021-02-27|archive-url=https://web.archive.org/web/20210227235011/https://www.cnbc.com/2021/02/26/johnson-and-johnson-covid-vaccine-fda-panel-recommends-emergency-use.html|dead-url=no}}</ref>。翌日，美国食药监局授予疫苗的紧急使用授权<ref name="FDA PR 20210227" /><ref name="FDA EUA" /><ref>{{cite news|url=https://www.washingtonpost.com/health/2021/02/27/johnson-and-johnson-covid-vaccine-fda/|newspaper=The Washington Post|date=2021-02-27|title=FDA authorizes Johnson & Johnson's single-shot coronavirus vaccine, adding to the nation's arsenal against the pandemic|vauthors=McGinley L, Johnson CY|accessdate=2021-04-20|archive-date=2021-02-28|archive-url=https://web.archive.org/web/20210228005521/https://www.washingtonpost.com/health/2021/02/27/johnson-and-johnson-covid-vaccine-fda/|dead-url=no}}</ref>。2月28日，[[美国疾病控制与预防中心|美国疾病控制与预防中心]]免疫实践咨询委员会（ACIP）建议为18岁以上的人群使用该疫苗<ref>{{cite news | vauthors=Feuer W | title=CDC panel recommends use of J&J's single-shot Covid vaccine, clearing way for distribution | website=CNBC | date=2021-02-28 | url=https://www.cnbc.com/2021/02/28/cdc-panel-recommends-use-of-jjs-single-shot-covid-vaccine.html | access-date=2021-02-28 | archive-date=2021-02-28 | archive-url=https://web.archive.org/web/20210228201952/https://www.cnbc.com/2021/02/28/cdc-panel-recommends-use-of-jjs-single-shot-covid-vaccine.html | dead-url=no }}</ref><ref name=":1">{{cite press release| title=Media Statement from CDC Director Rochelle P. Walensky, MD, MPH, on Signing the Advisory Committee on Immunization Practices' Recommendation to Use Janssen's COVID-19 Vaccine in People 18 and Older| website=Centers for Disease Control and Prevention (CDC)| date=2021-02-28| url=https://www.cdc.gov/media/releases/2021/s0228-JJ-vaccine.html| access-date=2021-03-01| archive-date=2021-03-23| archive-url=https://web.archive.org/web/20210323115538/https://www.cdc.gov/media/releases/2021/s0228-JJ-vaccine.html| dead-url=no}}</ref>，並於翌日起開始應用於[[美國2019冠狀病毒病疫苗接種計劃|美國2019冠狀病毒病疫苗接種計劃]]。

2021年4月初，美国国内多地发生了接种该款疫苗后出现头晕、呼吸急促等不良反应状况。其后佐治亚州、科罗拉多州以及北卡罗来纳州的部分地区已宣布暂停接种强生疫苗<ref>{{cite news |title=不良反应频现，美国多地暂停接种强生疫苗 |url=https://www.yicai.com/news/101016850.html |accessdate=2021-04-18 |work=央视新闻客户端 |date=2021-04-11 |archive-date=2021-04-21 |archive-url=https://web.archive.org/web/20210421013243/https://www.yicai.com/news/101016850.html |dead-url=no }}</ref>。

2021年4月13日，[[美国疾病控制与预防中心|美国疾病控制与预防中心]]和[[美国食品药品监督管理局|美国食品药品监督管理局]]宣布，他们将调查6例极其罕见的在注射疫苗後出現的{{link-en|脑静脉窦血栓|Cerebral venous sinus thrombosis}}形成病例，並建議暂停接種强生疫苗。6名病例中有一名妇女已经死亡，另有一名妇女緊急住院。<ref name=":6">{{Cite news|author=Weiland|first=Noah|author2=LaFraniere|first2=Sharon|last3=Zimmer|first3=Carl|date=13 April 2021|title=Johnson & Johnson Vaccinations Halt Across Country After Rare Clotting Cases Emerge|work=The New York Times|url=https://www.nytimes.com/2021/04/13/us/politics/johnson-johnson-vaccine-blood-clots-fda-cdc.html|accessdate=2021-04-13|archive-date=2021-06-07|archive-url=https://web.archive.org/web/20210607003343/https://www.nytimes.com/2021/04/13/us/politics/johnson-johnson-vaccine-blood-clots-fda-cdc.html|dead-url=no}}</ref><ref name=":5">{{Cite news|author=Erman|first=Michael|first2=Manas|author2=Mishra|date=2021-04-13|title=U.S. pauses use of J&J vaccine over rare blood clots, rollout delayed in Europe|publisher=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-johnson-johnson-va-idUSKBN2C01BC|accessdate=2021-04-13|archive-date=2021-04-13|archive-url=https://web.archive.org/web/20210413112309/https://www.reuters.com/article/us-health-coronavirus-johnson-johnson-va-idUSKBN2C01BC|dead-url=no}}</ref><ref name=":7">{{Cite news|first=Jacqueline|author=Howard|title=CDC and FDA recommend US pause use of Johnson & Johnson's Covid-19 vaccine over blood clot concerns|url=https://www.cnn.com/2021/04/13/health/johnson-vaccine-pause-cdc-fda/index.html|accessdate=2021-04-13|publisher=CNN|archive-date=2021-06-07|archive-url=https://web.archive.org/web/20210607002846/https://www.cnn.com/2021/04/13/health/johnson-vaccine-pause-cdc-fda/index.html|dead-url=no}}</ref>截至4月23日，美國有15人在接种强生新冠疫苗后出现严重血栓，其中3人死亡<ref>{{cite news |title=美国15人接种强生疫苗后出现严重血栓 3人死亡 |url=https://finance.sina.com.cn/chanjing/gsnews/2021-04-24/doc-ikmyaawc1492265.shtml |accessdate=2021-04-24 |archive-date=2021-04-24 |archive-url=https://web.archive.org/web/20210424103348/https://finance.sina.com.cn/chanjing/gsnews/2021-04-24/doc-ikmyaawc1492265.shtml |dead-url=no }}</ref>。當天，美国疾控控制与预防中心免疫实践咨询委员会建議应当在美国恢复使用强生疫苗<ref>{{cite news |title=美国疾控中心顾问建议恢复使用强生新冠疫苗 |url=https://www.voachinese.com/a/us-health-advisers-recommend-lifting-pause-on-johnson-and-johnson-vaccine-20210423/5864922.html |accessdate=2021-04-24 |archive-date=2021-05-01 |archive-url=https://web.archive.org/web/20210501153535/https://www.voachinese.com/a/us-health-advisers-recommend-lifting-pause-on-johnson-and-johnson-vaccine-20210423/5864922.html |dead-url=no }}</ref>。在暂停11天接种疫苗后的4月24日，美国疾控控制与预防中心与部分州属如印第安纳州、纽约州、弗吉尼亚州、密苏里州和密歇根州恢复使用强生疫苗<ref>{{Cite web|title=US states resume Johnson & Johnson vaccine in push to end Covid ‘nightmare’ {{!}} US news {{!}} The Guardian|url=https://amp.theguardian.com/us-news/2021/apr/24/johnson-and-johnson-vaccine-covid-coronavirus-us|accessdate=2021-04-26|work=amp.theguardian.com|archive-date=2021-06-02|archive-url=https://web.archive.org/web/20210602192021/https://amp.theguardian.com/us-news/2021/apr/24/johnson-and-johnson-vaccine-covid-coronavirus-us|dead-url=no}}</ref>。

===其他国家和地区===
2021年2月11日，[[圣文森特和格林纳丁斯|圣文森特和格林纳丁斯]]政府授予强生疫苗的紧急使用授权<ref>{{Cite web|title=Public Health (Emergency Authorisation of COVID-19 Vaccine) Rules, 2021|url=https://www.gov.vc/images/pdf_documents/SRO-Public_Health_Emergency_Authorisation_of_Covid-19_Vaccine.pdf|date=2021-02-11|access-date=2021-02-12|website=Government of Saint Vincent and the Grenadines|archive-date=2021-02-13|archive-url=https://web.archive.org/web/20210213124358/https://www.gov.vc/images/pdf_documents/SRO-Public_Health_Emergency_Authorisation_of_Covid-19_Vaccine.pdf|dead-url=yes}}</ref>。

2020年12月，强生与{{le|GAVI|GAVI}}疫苗联盟原则上签署了一项协议，以支持[[COVAX|COVAX]]计划。2021年2月19日，强生公司向世界卫生组织提交其“紧急使用清单”的正式请求和数据包；而参加COVAX的要求则是EUL。强生公司预计到2022年将为COVAX提供多达5亿剂的疫苗<ref>[https://www.prnewswire.com/news-releases/johnson--johnson-announces-submission-to-world-health-organization-for-emergency-use-listing-of-investigational-single-shot-janssen-covid-19-vaccine-candidate-301231645.html Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate] {{Wayback|url=https://www.prnewswire.com/news-releases/johnson--johnson-announces-submission-to-world-health-organization-for-emergency-use-listing-of-investigational-single-shot-janssen-covid-19-vaccine-candidate-301231645.html |date=20210219161712 }}, Johnson & Johnson (2021-02-19).</ref><ref name=":0" /><ref>{{Cite web|vauthors=Heeb G|title=Johnson & Johnson Applies For Emergency Use Vaccine Approval At W.H.O.|url=https://www.forbes.com/sites/ginaheeb/2021/02/19/johnson--johnson-applies-for-emergency-use-vaccine-approval-at-who/|access-date=2021-02-25|website=Forbes|archive-date=2021-02-20|archive-url=https://web.archive.org/web/20210220140403/https://www.forbes.com/sites/ginaheeb/2021/02/19/johnson--johnson-applies-for-emergency-use-vaccine-approval-at-who/|dead-url=no}}</ref>。

2021年2月25日，巴林授权疫苗的紧急使用<ref name="bahrain">{{cite news |title=Bahrain first to approve Johnson & Johnson COVID-19 vaccine for emergency use |website=Reuters |date=25 February 2021 |url=https://www.reuters.com/article/health-coronavirus-bahrain-idUSS8N2I4021 |first=Lisa |last=Barrington |access-date=2021-02-25 |archive-date=2021-03-10 |archive-url=https://web.archive.org/web/20210310014026/https://www.reuters.com/article/health-coronavirus-bahrain-idUSS8N2I4021 |dead-url=no }}</ref><ref name="abcnews.go.com">{{cite news | title=Bahrain becomes 1st nation to grant J&J shot emergency use | website=ABC News | date=2021-02-25 | url=https://abcnews.go.com/International/wireStory/bahrain-1st-nation-grant-jj-shot-emergency-76112143 | access-date=2021-02-25 | archive-date=2021-03-10 | archive-url=https://web.archive.org/web/20210310012735/https://abcnews.go.com/International/wireStory/bahrain-1st-nation-grant-jj-shot-emergency-76112143 | dead-url=no }}</ref>。

2021年2月26日，韩国食品及药品安全处开始审查强生公司的疫苗批准申请<ref>{{cite news |url=https://www.reuters.com/article/us-health-coronavirus-southkorea-vaccine/south-korea-launches-review-of-johnson-johnsons-covid-19-vaccine-idUSKBN2AR03K |first=Cynthia |last=Kim |first2=Sangmi |last2=Cha |title=South Korea launches review of Johnson & Johnson's COVID-19 vaccine |work=Reuters |date=2021-02-26 |accessdate=2021-04-20 |archive-date=2021-02-27 |archive-url=https://web.archive.org/web/20210227173305/https://www.reuters.com/article/us-health-coronavirus-southkorea-vaccine/south-korea-launches-review-of-johnson-johnsons-covid-19-vaccine-idUSKBN2AR03K |dead-url=no }}</ref>。

2020年11月下旬，强生公司向[[加拿大卫生部|加拿大卫生部]]提交滚动审核申请，以批准其疫苗<ref>{{cite news |first=Terry |last=Haig |url=https://www.rcinet.ca/en/2021/02/01/another-vaccine-submits-a-bid-for-health-canada-approval/ |title=Novavax submits its vaccine for Health Canada approval |work=Radio Canada International |date=2021-02-01 |accessdate=2021-04-20 |archive-date=2021-02-16 |archive-url=https://web.archive.org/web/20210216193558/https://www.rcinet.ca/en/2021/02/01/another-vaccine-submits-a-bid-for-health-canada-approval/ |dead-url=no }}</ref>。加拿大政府已与强生公司签订了供应1000万剂疫苗的订单，强生亦拥有再购买2800万剂疫苗的权利。2021年3月5日，该疫苗成为第四个获得加拿大卫生部批准使用的疫苗<ref>{{Cite web|url=https://www.cbc.ca/news/politics/johnson-johnson-covid19-vaccine-approved-1.5937900|title=Johnson & Johnson COVID-19 vaccine becomes 4th to receive Health Canada approval|website=CBC|access-date=2021-04-20|archive-date=2021-03-19|archive-url=https://web.archive.org/web/20210319010051/https://www.cbc.ca/news/politics/johnson-johnson-covid19-vaccine-approved-1.5937900|dead-url=no}}</ref>。

2021年2月，该疫苗在南非获得紧急授权<ref>{{cite web|title=SA is the first country to roll out Johnson & Johnson vaccine – what you need to know about the jab|url=https://www.businessinsider.co.za/covid-19-vaccine-johnson-johnson-what-we-know-2020-12|date=17 February 2021|access-date=4 March 2021|website=BusinessInsider|archive-date=2021-03-01|archive-url=https://web.archive.org/web/20210301185218/https://www.businessinsider.co.za/covid-19-vaccine-johnson-johnson-what-we-know-2020-12|dead-url=no}}</ref><ref>{{cite news | vauthors=Browdie B | title=South Africa to be first to use Johnson Johnson Covid-19 vaccine | website=Quartz | date=20 February 2021 | url=https://qz.com/africa/1973285/south-africa-to-be-first-to-use-johnson-johnson-covid-19-vaccine/ | access-date=4 March 2021 | archive-date=2021-03-03 | archive-url=https://web.archive.org/web/20210303131756/https://qz.com/africa/1973285/south-africa-to-be-first-to-use-johnson-johnson-covid-19-vaccine/ | dead-url=no }}</ref><ref name="WSJ 20210217">{{cite news |url=https://www.wsj.com/articles/south-africa-rolls-out-j-j-covid-19-vaccine-to-healthcare-workers-11613564630 |newspaper=The Wall Street Journal |date=2021-02-17 |vauthors=Steinhauser G |title=South Africa Rolls Out J&J Covid-19 Vaccine to Healthcare Workers |accessdate=2021-04-20 |archive-date=2021-02-18 |archive-url=https://web.archive.org/web/20210218182220/https://www.wsj.com/articles/south-africa-rolls-out-j-j-covid-19-vaccine-to-healthcare-workers-11613564630 |dead-url=no }}</ref>。同年4月，南非暂停使用该疫苗<ref name="iolTurner13042021">{{cite web | last=Turner | first=Kelly-Jane | title=This is why SA is suspending its J&J vaccine roll-out | website=IOL | date=2021-04-13 | url=https://www.iol.co.za/news/politics/this-is-why-sa-is-suspending-its-j-and-j-vaccine-roll-out-84618c38-ab59-490e-af76-ff732fe43912 | access-date=2021-04-14 | archive-date=2021-04-14 | archive-url=https://web.archive.org/web/20210414024006/https://www.iol.co.za/news/politics/this-is-why-sa-is-suspending-its-j-and-j-vaccine-roll-out-84618c38-ab59-490e-af76-ff732fe43912 | dead-url=no }}</ref>。南非在4月28日恢復為醫護人員接種強生疫苗<ref name="South Africa resume on April 28">{{cite news |title=South Africa resumes giving J&J jabs to health care workers |url=https://www.seattletimes.com/nation-world/world/south-africa-resumes-giving-jj-jabs-to-health-care-workers/ |accessdate=2021-04-29 |work=The Seattle Times |date=2021-04-28 |archive-date=2021-05-15 |archive-url=https://web.archive.org/web/20210515055521/https://www.seattletimes.com/nation-world/world/south-africa-resumes-giving-jj-jabs-to-health-care-workers/ |dead-url=no }}</ref>。

2021年3月底，该疫苗在哥伦比亚获得紧急授权<ref name=Colombia>{{cite news |vauthors=Acosta LJ |location=Bogotá |title=Colombia grants emergency use for J&J coronavirus vaccine |url=https://www.reuters.com/article/health-coronavirus-colombia/colombia-grants-emergency-use-for-jj-coronavirus-vaccine-idUSL1N2LO01O |access-date=2021-03-25 |work=Reuters |date=2021-03-25 |archive-date=2021-06-25 |archive-url=https://web.archive.org/web/20210625093324/https://www.reuters.com/business/healthcare-pharmaceuticals/colombia-grants-emergency-use-jj-coronavirus-vaccine-2021-03-26/ |dead-url=no }}</ref>。

2021年4月，澳大利亚政府表示，将不会购买强生疫苗，并强调“目前不打算再购买任何腺病毒疫苗”<ref name=AbcAusApril132021>{{cite news |last=Lowrey |first=Tom |title=Johnson & Johnson's one-dose COVID-19 vaccine won't be coming to Australia due to AstraZeneca similarities |url=https://www.abc.net.au/news/2021-04-13/johnson-johnson-covid-19-vaccine-australia/100064454 |work=ABC News |date=2021-04-13 |accessdate=2021-04-20 |archive-date=2021-04-13 |archive-url=https://web.archive.org/web/20210413013022/https://www.abc.net.au/news/2021-04-13/johnson-johnson-covid-19-vaccine-australia/100064454 |dead-url=no }}</ref><ref>{{cite news | last=Karp | first=Paul | title=Australia won't buy Johnson & Johnson's one-dose Covid vaccine due to AstraZeneca similarities | work=The Guardian | date=2021-04-12 | url=http://www.theguardian.com/society/2021/apr/13/australia-wont-buy-johnson-johnsons-one-dose-covid-vaccine-due-to-astrazeneca-similarities | access-date=2021-04-12 | archive-date=2021-04-12 | archive-url=https://web.archive.org/web/20210412224207/https://www.theguardian.com/society/2021/apr/13/australia-wont-buy-johnson-johnsons-one-dose-covid-vaccine-due-to-astrazeneca-similarities | dead-url=no }}</ref>。

2021年5月27日，台灣的宗教團體[[國際佛光會|國際佛光會]]發函給[[中央流行疫情指揮中心|中央流行疫情指揮中心]]，申請輸入50萬劑强生疫苗捐贈給政府供醫護及神職人員接種，不過之後嬌生公司表示僅會直接與政府洽談疫苗採購，不透過第三方<ref>{{cite news |author1=陳凱俊 |title=嬌生疫苗「只和政府談」　外媒爆：去年就和台灣當局私下協商 |url=https://www.mirrormedia.mg/story/20210604edi046/ |accessdate=2021-09-08 |work=鏡週刊 |date=2021-06-04 |archive-date=2021-09-08 |archive-url=https://web.archive.org/web/20210908033453/https://www.mirrormedia.mg/story/20210604edi046/ |dead-url=no }}</ref>。

2021年5月28日，英國政府向強生疫苗批出緊急使用許可，而該等疫苗將於[[英國2019冠狀病毒病疫苗接種計劃|英國2019冠狀病毒病疫苗接種計劃]]中應用<ref>{{cite news|url=https://www2.hkej.com/instantnews/current/article/2811255/%E8%8B%B1%E5%9C%8B%E6%89%B9%E5%87%86%E4%BD%BF%E7%94%A8%E5%BC%B7%E7%94%9F%E6%96%B0%E5%86%A0%E7%97%85%E6%AF%92%E7%96%AB%E8%8B%97|title=英國批准使用強生新冠病毒疫苗|work=信報財經新聞|date=2021-05-28|accessdate=2021-05-29}}</ref>。

2021年6月13日，韩国大邱市一名38岁市民在接种强生疫苗三天后死亡，这是韩国报告的首例强生疫苗接种者死亡案例，卫生部门将着手调查死因<ref>{{cite news |last1=林煇智 |first1=文 / |title=韩国出现首起强生疫苗接种者死亡病例 |url=https://www.zaobao.com.sg/realtime/world/story20210613-1155739 |accessdate=2021-06-14 |work=联合早报 |date=2021-06-13 |archive-date=2021-06-15 |archive-url=https://web.archive.org/web/20210615053952/https://www.zaobao.com.sg/realtime/world/story20210613-1155739 |dead-url=no }}</ref>。

==争议==
{{le|美國天主教主教團|United States Conference of Catholic Bishops}}表示，對強生疫苗表达「道德關切」。美國天主教主教會議和新奧爾良等多個教區先後發聲明，指強生使用[[流產|流產]][[胎兒|胎兒]]的細胞生產疫苗，已經受「道德污染」，注射疫苗等同在道德上妥協，呼籲信徒在有選擇情況下，應盡量接種其他疫苗<ref name=bbccn>{{cite news |title=在疫情最嚴重的美國，民眾選擇新冠疫苗的標凖 |url=https://www.bbc.com/zhongwen/trad/world-56473782 |accessdate=2021-04-19 |work=BBC News 中文 |date=2021-03-21 |language=zh-hant |archive-date=2021-06-05 |archive-url=https://web.archive.org/web/20210605211947/https://www.bbc.com/zhongwen/trad/world-56473782 |dead-url=no }}</ref><ref name=am730>{{cite news |title=新冠疫苗｜美天主教籲杯葛 強生：疫苗無流產胎兒組織細胞 - 新聞 |url=https://www.am730.com.hk/news/%E6%96%B0%E8%81%9E/%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97%EF%BD%9C%E7%BE%8E%E5%A4%A9%E4%B8%BB%E6%95%99%E7%B1%B2%E6%9D%AF%E8%91%9B-%E5%BC%B7%E7%94%9F%EF%BC%9A%E7%96%AB%E8%8B%97%E7%84%A1%E6%B5%81%E7%94%A2%E8%83%8E%E5%85%92%E7%B5%84%E7%B9%94%E7%B4%B0%E8%83%9E-258444 |accessdate=2021-04-19 |work=am730 |date=2021-03-05 |language=zh-hk |archive-date=2021-04-21 |archive-url=https://web.archive.org/web/20210421053436/https://www.am730.com.hk/news/%E6%96%B0%E8%81%9E/%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97%EF%BD%9C%E7%BE%8E%E5%A4%A9%E4%B8%BB%E6%95%99%E7%B1%B2%E6%9D%AF%E8%91%9B-%E5%BC%B7%E7%94%9F%EF%BC%9A%E7%96%AB%E8%8B%97%E7%84%A1%E6%B5%81%E7%94%A2%E8%83%8E%E5%85%92%E7%B5%84%E7%B9%94%E7%B4%B0%E8%83%9E-258444 |dead-url=no }}</ref><ref name=cnn-us-bishops>{{cite news |title=Some US bishops discourage Catholics from getting Johnson & Johnson vaccine if others are available |url=https://www.cnn.com/2021/03/03/health/bishops-catholics-johnson-and-johnson-vaccine/index.html |access-date=2021-03-03 |publisher=CNN |date=2021-03-03 |archive-date=2021-03-11 |archive-url=https://web.archive.org/web/20210311004829/https://www.cnn.com/2021/03/03/health/bishops-catholics-johnson-and-johnson-vaccine/index.html |dead-url=no }}</ref><ref name=nebraska-med>{{Cite web|title=You asked, we answered: Do the COVID-19 vaccines contain aborted fetal cells? {{!}} Nebraska Medicine Omaha, NE|url=https://www.nebraskamed.com/COVID/you-asked-we-answered-do-the-covid-19-vaccines-contain-aborted-fetal-cells|access-date=2021-03-24|website=www.nebraskamed.com|archive-date=2021-03-24|archive-url=https://web.archive.org/web/20210324020756/https://www.nebraskamed.com/COVID/you-asked-we-answered-do-the-covid-19-vaccines-contain-aborted-fetal-cells|dead-url=no}}</ref>。教宗[[方濟各_(教宗)|方濟各]]则认为這類疫苗「在道德上是可以接受的」<ref name=cnn-us-bishops /><ref name=VaticanNote>{{Cite web|title=Note on the morality of using some anti-Covid-19 vaccines (21 December 2020)|url=https://www.vatican.va/roman_curia/congregations/cfaith/documents/rc_con_cfaith_doc_20201221_nota-vaccini-anticovid_en.html|access-date=2021-03-24|website=www.vatican.va|archive-date=2021-03-24|archive-url=https://web.archive.org/web/20210324211936/https://www.vatican.va/roman_curia/congregations/cfaith/documents/rc_con_cfaith_doc_20201221_nota-vaccini-anticovid_en.html|dead-url=no}}</ref><ref name=bbccn/>。另外美国康涅狄格州哈特福德大主教（Archbishop of Hartford）和其他當地神職人員在一份聲明中宣佈，所有居民「應該憑良心自由地接種目前可用的疫苗……為了自己的健康和公共利益」<ref name=bbccn/>。而強生公司其後發表聲明，否認有關說法，指疫苗中沒有流產胎兒組織細胞<ref name=am730/>。

==参考资料==
{{reflist|30em}}

==外部链接==
{{scholia}}
* {{cite web | title=Janssen COVID-19 Vaccine (Johnson & Johnson) | publisher=[[美国疾病预防控制中心|美国疾病预防控制中心]] | url=https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html | access-date=2021-04-14 | archive-date=2021-03-29 | archive-url=https://web.archive.org/web/20210329230548/https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html | dead-url=no }}
* {{cite web | title=强生公司的杨森COVID-19疫苗概述 | publisher=[[美国疾病预防控制中心|美国疾病预防控制中心]] | url=https://chinese.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html | access-date=2021-04-20 | archive-date=2021-05-13 | archive-url=https://web.archive.org/web/20210513200802/https://chinese.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html | dead-url=no }}

{{COVID-19}}
{{疫苗}}
[[Category:2020年面世的產品|Category:2020年面世的產品]]
[[Category:强生公司|Category:强生公司]]
[[Category:楊森製藥|Category:楊森製藥]]
[[Category:2019冠状病毒病疫苗|Category:2019冠状病毒病疫苗]]
[[Category:临床试验|Category:临床试验]]
[[Category:腺病毒科|Category:腺病毒科]]
[[Category:CS1加泰罗尼亚语来源_(ca)|Category:CS1加泰罗尼亚语来源 (ca)]]
[[Category:Drugs_with_non-standard_legal_status|Category:Drugs with non-standard legal status]]
[[Category:未分配ATC的藥物|Category:未分配ATC的藥物]]
[[Category:病毒载体疫苗|Category:病毒载体疫苗]]